BMPRII is a direct target of miR-21

Acta Biochimica et Biophysica Sinica

Volumn 41, Issue 7, 2009, Pages 618-623

  Qin, Wenming ^a   Zhao, Botao ^a   Shi, Yi ^a   Yao, Chengguo ^a   Jin, Li ^b   Jin, Youxin ^a  

^a Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^b St Luke's Hospital   (China)

Author keywords

BMPRII; MicroRNA; MiR 21; Prostate cancer; Target

Indexed keywords

BMPR2 PROTEIN, HUMAN; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; MICRORNA; MIRN21 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; ANIMAL; ARTICLE; BINDING SITE; CELL LINE; GENETICS; HUMAN; METABOLISM; NUCLEOTIDE SEQUENCE; REPORTER GENE; SEQUENCE ALIGNMENT;

3' UNTRANSLATED REGIONS; ANIMALS; BASE SEQUENCE; BINDING SITES; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE II; CELL LINE; CONSERVED SEQUENCE; GENES, REPORTER; HUMANS; MICRORNAS; SEQUENCE ALIGNMENT;

ANIMALIA;

EID: 67651210932     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmp049     Document Type: Article

References (31)

1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116: 281-297.
2. Eulalio A, Huntzinger E and Izaurralde E. Getting to the root of miRNA-mediated gene silencing. Cell 2008, 132: 9-14.
3. Yao C, Zhao B, Li W, Li Y, Qin W, Huang B and Jin Y. Cloning of novel repeat-associated small RNAs derived from hairpin precursors in Oryza sativa. Acta Biochim Biophys Sin 2007, 39: 829-834.
4. Wu L and Belasco JG. Let me count the ways: mechanisms of gene regulation by miRNAs and siRNAs. Mol Cell 2008, 29: 1-7.
5. Yao C, Ge L, Li Y, Zhao B, Li C, Ruan K and Lin H, et al. Expression and characterization of rice putative PAUSED gene. Acta Biochim Biophys Sin 2008, 40: 893-900.
6. Filipowicz W, Bhattacharyya SN and Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 2008, 9: 102-114.
7. Asli NS, Pitulescu ME and Kessel M. MicroRNAs in organogenesis and disease. Curr Mol Med 2008, 8: 698-710.
8. Osaki M, Takeshita F and Ochiya T. MicroRNAs as biomarkers and therapeutic drugs in human cancer. Biomarkers 2008, 13: 658-670.
9. Yang B, Lu Y and Wang Z. Control of cardiac excitability by microRNAs. Cardiovasc Res 2008, 79: 571-580.
10. Huang B, Li W, Zhao B, Xia C, Liang R, Ruan K and Jing N, et al. MicroRNA expression profiling during neural differentiation of mouse embryonic carcinoma P19 cells. Acta Biochim Biophys Sin 2009, 41: 231-236.
11. Rogaev EI, Borinskaia SA, Islamgulov DV and Grigorenko AP. Human microRNA in norm and pathology. Mol Biol (Mosk) 2008, 42: 751-764.
12. Tong AW and Nemunaitis J. Modulation of miRNA activity in human cancer: a new paradigm for cancer gene therapy? Cancer Gene Ther 2008, 15: 341-355.
13. Urbich C, Kuehbacher A and Dimmeler S. Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovasc Res 2008, 79: 581-588.
14. Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A and Lund AH. Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem 2008, 283: 1026-1033.
15. Zhu S, Si ML, Wu H and Mo YY. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem 2007, 282: 14328-14336.
16. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST and Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007, 133: 647-658.
17. Li B. Bone morphogenetic protein-Smad pathway as drug targets for osteoporosis and cancer therapy. Endocr Metab Immune Disord Drug Targets 2008, 8: 208-219.
18. Nie X, Luukko K and Kettunen P. BMP signalling in craniofacial development. Int J Dev Biol 2006, 50: 511-521.
19. Granjeiro JM, Oliveira RC, Bustos-Valenzuela JC, Sogayar MC and Taga R. Bone morphogenetic proteins: from structure to clinical use. Braz J Med Biol Res 2005, 38: 1463-1473.
20. Rigelsky CM, Jennings C, Lehtonen R, Minai OA, Eng C and Aldred MA. BMPR2 mutation in a patient with pulmonary arterial hypertension and suspected hereditary hemorrhagic telangiectasia. Am J Med Genet A 2008, 146: 2551-2556.
21. Hassel S, Eichner A, Yakymovych M, Hellman U, Knaus P and Souchelnytskyi S. Proteins associated with type II bone morphogenetic protein receptor (BMPR-II) and identified by two-dimensional gel electrophoresis and mass spectrometry. Proteomics 2004, 4: 1346-1358.
22. Lavery K, Swain P, Falb D and Alaoui-Ismaili MH. BMP-2/4 and BMP-6/7 differentially utilize cell surface receptors to induce osteoblas-tic differentiation of human bone marrow-derived mesenchymal stem cells. J Biol Chem 2008, 283: 20948-20958.
23. Southwood M, Jeffery TK, Yang X, Upton PD, Hall SM, Atkinson C and Haworth SG, et al. Regulation of bone morphogenetic protein signalling in human pulmonary vascular development. J Pathol 2008, 214: 85-95.
24. McKay RD. Stem cell biology and neurodegenerative disease. Philos Trans R Soc Lond B Biol Sci 2004, 359: 851-856.
25. Ye L, Lewis-Russell JM, Kyanaston HG and Jiang WG. Bone morpho-genetic proteins and their receptor signaling in prostate cancer. Histol Histopathol 2007, 22: 1129-1147.
26. Weston AD, Rosen V, Chandraratna RA and Underhill TM. Regulation of skeletal progenitor differentiation by the BMP and retinoid signaling pathways. J Cell Biol 2000, 148: 679-690.
27. Chen D, Zhao M and Mundy GR. Bone morphogenetic proteins. Growth Factors 2004, 22: 233-241.
28. Abramowicz MJ, Van Haecke P, Demedts M and Delcroix M. Primary pulmonary hypertension after amfepramone (diethylpropion) with BMPR2 mutation. Eur Respir J 2003, 22: 560-562.
29. Krichevsky AM and Gabriely G. miR-21: a small multi-faceted RNA. J Cell Mol Med 2009, 13: 39-53.
30. Hoosein NM. Neuroendocrine and immune mediators in prostate cancer progression. Front Biosci 1998, 3: 1274-1279.
31. Kim IY, Lee DH, Lee DK, Ahn HJ, Kim MM, Kim SJ and Morton RA. Loss of expression of bone morphogenetic protein receptor type II in human prostate cancer cells. Oncogene 2004, 23: 7651-7659.